Clinical trials: Hepatitis, Viral, Human
Hepatitis B Virus (HBV), Lung Transplant Recipient
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
- Trial name
- CLEAR-HBV (NCT07189377)
- Testing
- Entecavir, HBIG, EVLP UV Light Treatment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, Chronic, Pregnancy; Infection
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
This is a multicenter, single arm study of Sofosbuvir/Velpatasvir (SOF/VEL) for treatment of chronic hepatitis C infection during pregnancy.
- Trial name
- STORC (NCT05140941)
- Testing
- Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Catherine Anne Chappell
Chronic Hepatitis C
Effect of Camel Milk on Chronic Hepatitis C
Camel milk as the new modality for treatment of chronic hepatitis C. The purpose of this study is to evaluate effectiveness and safety of camel milk in combination with Peginterferon Alfa-2a and Ribavirin in genotype 2,3 chronic…
- Trial name
- HCV (NCT02216045)
- Testing
- Peginterferon, Ribavirin, camel milk, Peginterferon, Ribavirin
- Where
- 2 sites in Iran
- Volunteers
- 40 people
- Sponsor
- Mashhad University of Medical Sciences
Hepatitis C
Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment
After a liver transplant, the hepatitis C virus (which destroyed one's own liver) eventually comes back. In many patients, this will eventually cause the loss of the new liver and can also confuse the doctors taking care of them…
- Trial name
- NCT00167557
- Testing
- Pegylated Interferon, Ribavirin, Liver Biopsy
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Cancer, Liver Cirrhosis
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign…
- Conditions
- Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B
- Trial name
- ELITE (NCT05181826)
- Testing
- Multi-analyte Blood Test
- Where
- 7 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Helio Genomics
Viral Hepatitis
Seroepidemiology of Viral Hepatitis in Hong Kong
Immunisation policies have strong influences on the epidemiology of hepatitis A and B infection. In Hong Kong, vaccines against both viruses have been available through different channels and programmes in the past 3 decades.
- Trial name
- NCT04371276
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,888 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Hepatitis C, Chronic, Liver Diseases
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)
The purpose of this study is to validate the first round HCV early dynamics discovery within a larger population.
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Interferon Deficiency
- Trial name
- sIFN-pred2 (NCT01760148)
- Testing
- interferon alpha 2b
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Junqi Niu
Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Patients with chronic hepatitis B histologically confirmed of early cirrhosis S4 (similar to metavir F4, Ishak 5/6) are randomly assigned in a 1:1 ratio.
- Trial name
- NCT01938820
- Testing
- entecavir, Thymosin-α
- Where
- 21 sites in China
- Volunteers
- 82 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis C
SMV + SOF With/Without RBV for IFN-II Patients With CHC
Prior trials have shown that many G1 CHC patients are ineligible or intolerant to pegylated (PEG)-based regimens due to prior severe side effects, worsening of cytopenias, exacerbation of underlying psychiatric disorders, or…
- Trial name
- NCT02214420
- Testing
- Simeprevir, Sofosbuvir, Ribavirin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- SC Liver Research Consortium, LLC
HCV Infection, HCV Coinfection
Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents
Study about the improvement of cognitive, psychopathological and functional abilities in Hepatitis C Virus (HCV) infected patients after eradication of the virus with direct antiviral agents.
- Trial name
- NCT03508115
- Volunteers
- 80 people
- Sponsor
- Corporacion Parc Tauli
Chronic Hepatitis C
4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin (standard of care) for 48 weeks.
- Trial name
- NCT00763568
- Testing
- Nitazoxanide, Peginterferon alfa-2a
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Chronic Hepatitis B
Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)
The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia
- Trial name
- NCT00338780
- Where
- China
- Sponsor
- Chinese University of Hong Kong
Hepatitis C Virus Infection
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
This is a follow-up study with no treatment and only samples being collected.
- Trial name
- NCT00872196
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®)…
- Trial name
- NCT01271790
- Testing
- Tegobuvir (GS-9190), GS-9451, Pegasys®
- Where
- 144 sites in United States, Austria and 6 more
- Volunteers
- 245 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon
Title Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin with or without Interferon among Pakistani Population: A real life trial Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS) Study Design Endpoint…
- Trial name
- HEATS (NCT02804386)
- Testing
- Sofosbuvir
- Where
- Pakistan
- Volunteers
- 573 people
- Sponsor
- PharmEvo Pvt Ltd
Hepatitis B
Simvastatin for the Treatment of Chronic Hepatitis B
The investigators have shown robust in vitro anti-hepatitis B activity of simvastatin alone and synergistic activity with all four FDA-approved anti-hepatitis B oral drugs tested.
- Trial name
- NCT00994773
- Testing
- Simvastatin, Tenofovir, Entecavir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Bader, Ted, M.D.
C Hepatitis, Tri Therapy
Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy
The risk of severe anemia is increased in patients treated by tri-therapy compared to patients treated by bitherapy. The underlying mechanisms involved in this toxicity remain unexplored but could also depend on the global…
- Trial name
- Ribatela (NCT01716403)
- Testing
- Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Grenoble
Hepatitis C, Chronic
A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
This study will provide vaniprevir 600 mg or 300 mg twice daily in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) to participants with chronic hepatitis C virus (HCV) infection who did not achieve viral…
- Trial name
- NCT00943761
- Testing
- Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
- Trial name
- NCT01463683
- Testing
- 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B
The objective of this study was to evaluate the efficacy and safety of TVAX-008 Injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial in NAs-treated subjects with chronic…
- Trial name
- NCT07190742
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.